Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Four glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used in children and adolescents with obesity or overweight. This network meta-analysis was conducted to compare the efficacy and safety of these regimens. Embase, PubMed, and Scopus were searched on March 2023 and updated in June 2024 for eligible randomized controlled trials (RCTs). The primary efficacy outcomes were mean difference in actual body weight, BMI (body mass index), BMI z score, and waist circumference. Safety outcomes included nausea, vomiting, diarrhea, abdominal pain, injection-site reaction, and hypoglycemia. Eleven RCTs with 953 participants were eligible. Semaglutide exhibited greater effects in reducing weight, BMI, and BMI z score versus the placebo. Semaglutide was associated with greater weight loss and BMI z score reduction in comparison with exenatide, liraglutide, and dulaglutide. Semaglutide also significantly decreased BMI than exenatide. None of the four GLP-1 RAs were associated with higher risks of diarrhea, headache, and abdominal pain versus the placebo. Liraglutide was more likely to cause nausea, vomiting, hypoglycemia, and injection-site reactions than the placebo. Liraglutide also had higher odds of causing injection-site reactions than other GLP-1 RAs. Semaglutide appeared to be the most effective and safe option among four GLP-1 RAs in children and adolescents with obesity or overweight.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The analysis showed that semaglutide was associated with greater weight loss and BMI Z-score reductions than exenatide, liraglutide, and dulaglutide.”
From Managing early-onset type 2 diabetes in the individual and at the population level (2025) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Tirzepatide, a promising agent that exhibits GLP-1/GIP co-agonism, significantly reduced body weight across all doses in adults with obesity [53,54].”
BackgroundMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“Liraglutide and semaglutide, as glucagon-like peptide-1 receptor agonists (GLP-1 RAs), enhance glucose-dependent insulin secretion, slow down gastric emptying, increase satiety, and reduce food intake [14].”
BackgroundPrevalence of Obesity and Severe Obesity in US Children, 1999–2016
Skinner, A. C., Ravanbakht, S. N., Skelton, J. A., Perrin, E. M., & Armstrong, S. C. (2018) · Pediatrics · doi:10.1542/peds.2017-3459 · Cited by 1,412 · cited 1×
“Approximately one-third of children and adolescents in the United States are diagnosed with overweight or obesity [1].”
BackgroundSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“Safety outcomes were frequently reported adverse events, including the proportion of patients with nausea, vomiting, diarrhea, abdominal pain, headache, injection-site reaction, and hypoglycemia as defined by the American Diabetes Association [57].”
BackgroundHampl, S. E., Hassink, S. G., Skinner, A. C., Armstrong, S. C., Barlow, S. E., Bolling, C. F., Avila Edwards, K. C., Eneli, I., Hamre, R., Joseph, M. M., et al. (2023) · Pediatrics · doi:10.1542/peds.2022-060640 · Cited by 1,389 · cited 2×
“Overweight was defined as a BMI between the 85th and 95th percentiles for age and sex, obesity as BMI ≥ 30 kg/m 2 , or in the 95th or higher percentiles, and severe obesity as BMI ≥ 1.2 times the 95th percentile or BMI ≥ 35 kg/m 2 [16].”
BackgroundInfluentialOnce-weekly semaglutide in adolescents with obesity
Weghuber, D., Barrett, T., Barrientos-Pérez, M., Gies, I., Hesse, D., Jeppesen, O. K., Kelly, A. S., Mastrandrea, L. D., Sørrig, R., & Arslanian, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208601 · Cited by 730 · cited 8×
“The effects of semaglutide, liraglutide, and exenatide on scores for the impact of weight on quality of life—Kids (IWQOL–Kids) were measured [24,27,29].”
BackgroundInfluentialA Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723 · cited 7×
“The effects of semaglutide, liraglutide, and exenatide on scores for the impact of weight on quality of life—Kids (IWQOL–Kids) were measured [24,27,29].”
BackgroundMethodInfluentialJendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299 · cited 1×
“Furthermore, amylin, as a potential enhancer of the effects of GLP-1 on satiation signals, may synergistically interact with GLP-1 and augment the efficacy of leptin [55].”
BackgroundGLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244 · cited 1×
“GIP directly affects the central nervous system by suppressing food intake and amplifying the anorexigenic properties of GLP-1 [52].”
BackgroundIqbal, J., Wu, H., Hu, N., Zhou, Y., Li, L., Xiao, F., Wang, T., Jiang, H., Xu, S., Huang, B., et al. (2022) · Obesity Reviews · doi:10.1111/obr.13435 · Cited by 179 · cited 3×
“Similarly, in adults with obesity and without diabetes, semaglutide demonstrated significantly higher odds of achieving more significant reductions in actual weight and BMI compared with the placebo and liraglutide [33,34].”
BackgroundMahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09699-1 · Cited by 166
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · cited 1×
“Studies on adults have suggested that the weight loss effects of GLP-1 RAs are associated with decreases in waist circumference, central fat mass, and total body fat [35–37].”
BackgroundAlkhezi, O. S., Alahmed, A. A., Alfayez, O. M., Alzuman, O. A., Almutairi, A. R., & Almohammed, O. A. (2023) · Obesity Reviews · doi:10.1111/obr.13543 · Cited by 139
Kosiborod, M. N., Bhatta, M., Davies, M., Deanfield, J. E., Garvey, W. T., Khalid, U., Kushner, R., Rubino, D. M., Zeuthen, N., & Verma, S. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14890 · Cited by 127 · cited 1×
“A comparison between different GLP-1 RAs could not be conducted in this NMA due to the lack of data from original RCTs. Previous studies found that semaglutide decreased triacylglycerol, LDL, and non-HDL cholesterol levels in patients with diabetes and obesity [43,44].”
BackgroundCurrent and future pharmacotherapies for obesity in children and adolescents
Kelly, A. S. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00858-9 · Cited by 54 · cited 1×
“Therefore, an engagement in lifestyle modification interventions and the use of medications should be continued indefinitely if treatments are well tolerated [48].”
BackgroundRisk Factors, Clinical Consequences, Prevention, and Treatment of Childhood Obesity
Shaban Mohamed, M. A., AbouKhatwa, M. M., Saifullah, A. A., Hareez Syahmi, M., Mosaad, M., Elrggal, M. E., Dehele, I. S., & Elnaem, M. H. (2022) · Children · doi:10.3390/children9121975 · Cited by 52 · cited 1×
“Obesity is strongly associated with cardiovascular disease, hypertension, diabetes, non-alcoholic fatty liver diseases, polycystic ovarian syndrome, sleep apnea, as well as musculoskeletal and mental health disorders [3,4].”
BackgroundSun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Endocrine · doi:10.1007/s12020-014-0373-0 · Cited by 44
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00423-z · Cited by 43
Guerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40
Liu, F., Yang, Q., Zhang, H., Zhang, Y., Yang, G., Ban, B., Li, Y., & Zhang, M. (2022) · PLOS ONE · doi:10.1371/journal.pone.0270899 · Cited by 30
Research works printed but not linked: 33
- Simmonds, 2016, Predicting adult obesity from childhood obesity: A systematic review and meta-analysis, Obes. Rev., 17, 95, 10.1111/obr.12334 · DOI · Paper page
- Rahmouni, 2005, Obesity-associated hypertension: New insights into mechanisms, Hypertension, 45, 9, 10.1161/01.HYP.0000151325.83008.b4 · DOI · Paper page
- Lister, 2023, Child and adolescent obesity, Nat. Rev. Dis. Primers, 9, 24, 10.1038/s41572-023-00435-4 · DOI · Paper page
- Grossman, 2017, Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement, JAMA, 317, 2417, 10.1001/jama.2017.6803 · DOI · Paper page
- Skinner, 2023, Appraisal of Clinical Care Practices for Child Obesity Treatment. Part I: Interventions, Pediatrics, 151, e2022060642, 10.1542/peds.2022-060642 · DOI
- Woodard, 2020, Medications for the treatment of obesity in adolescents, Ther. Adv. Endocrinol. Metab., 11, 2042018820918789, 10.1177/2042018820918789 · DOI · Paper page
- Gourgari, 2021, Use of glucagon-like peptide-1 receptor agonists for pediatric patients with obesity and diabetes: The providers’ perspectives, Pediatr. Diabetes, 22, 872, 10.1111/pedi.13234 · DOI
- Apperley, 2022, Childhood obesity: A review of current and future management options, Clin. Endocrinol., 96, 288, 10.1111/cen.14625 · DOI
- Ryan, 2021, Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis, J. Pediatr., 236, 137, 10.1016/j.jpeds.2021.05.009 · DOI · Paper page
- Arslanian, 2022, Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes, N. Engl. J. Med., 387, 433, 10.1056/NEJMoa2204601 · DOI · Paper page
- Klein, 2014, Liraglutide’s safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: A randomized, double-blind, placebo-controlled trial, Diabetes Technol. Ther., 16, 679, 10.1089/dia.2013.0366 · DOI · Paper page
- Tamborlane, 2019, Liraglutide in children and adolescents with type 2 diabetes, N. Engl. J. Med., 381, 637, 10.1056/NEJMoa1903822 · DOI · Paper page
- Danne, 2017, Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12–17 Years, J. Pediatr., 181, 146, 10.1016/j.jpeds.2016.10.076 · DOI · Paper page
- Mastrandrea, 2019, Liraglutide effects in a paediatric (7-11 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics, Pediatr. Obes., 14, e12495, 10.1111/ijpo.12495 · DOI · Paper page
- Weghuber, 2020, A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide in adolescents with obesity, Pediatr. Obes., 15, e12624, 10.1111/ijpo.12624 · DOI · Paper page
- Kelly, 2013, The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: A randomized, placebo-controlled, clinical trial, JAMA Pediatr., 167, 355, 10.1001/jamapediatrics.2013.1045 · DOI · Paper page
- Fox, 2022, Exenatide for weight-loss maintenance in adolescents with severe obesity: A randomized, placebo-controlled trial, Obesity, 30, 1105, 10.1002/oby.23395 · DOI
- Kelly, 2012, Exenatide as a weight-loss therapy in extreme pediatric obesity: A randomized, controlled pilot study, Obesity, 20, 364, 10.1038/oby.2011.337 · DOI · Paper page
- Holst, 2017, Semaglutide seems to be more effective the other GLP-1Ras, Ann. Transl. Med., 5, 505, 10.21037/atm.2017.11.10 · DOI · Paper page
- Drozdz, D., Alvarez-Pitti, J., Wójcik, M., Borghi, C., Gabbianelli, R., Mazur, A., Herceg-Čavrak, V., Lopez-Valcarcel, B.G., Brzeziński, M., and Lurbe, E. (2021). Obesity and Cardiometabolic Risk Factors: From Childhood to Adulthood. Nutrients, 13. · DOI · Paper page
- Clifton, 2018, Relationship Between Changes in Fat and Lean Depots Following Weight Loss and Changes in Cardiovascular Disease Risk Markers, J. Am. Heart Assoc., 7, e008675, 10.1161/JAHA.118.008675 · DOI
- Vanderwall, C., Randall Clark, R., Eickhoff, J., and Carrel, A.L. (2017). BMI is a poor predictor of adiposity in young overweight and obese children. BMC Pediatr., 17. · DOI · Paper page
- Overgaard, 2021, Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes, Cell Rep. Med., 2, 100387, 10.1016/j.xcrm.2021.100387 · DOI · Paper page
- Zhao, 2022, Comparison of weight loss and adverse events of obesity drugs in children and adolescents: A systematic review and meta-analysis, Expert. Rev. Clin. Pharmacol., 15, 1119, 10.1080/17512433.2022.2117152 · DOI
- 2015, Rebound effect of intervention programs to reduce overweight and obesity in children and adolescents systematic review, Nutr. Hosp., 32, 2508
- Mamrot, 2019, The association of the executive functions with overweight and obesity indicators in children and adolescents: A literature review, Neurosci. Biobehav. Rev., 107, 59, 10.1016/j.neubiorev.2019.08.021 · DOI · Paper page
- Liang, J.H., Zhao, Y., Chen, Y.C., Jiang, N., Zhang, S.X., Huang, S., Kakaer, A., and Chen, Y.J. (2022). Face-to-face physical activity incorporated into dietary intervention for overweight/obesity in children and adolescents: A Bayesian network meta-analysis. BMC Med., 20. · DOI
- Epstein, 2023, Family-Based Behavioral Treatment for Childhood Obesity Implemented in Pediatric Primary Care: A Randomized Clinical Trial, JAMA, 329, 1947, 10.1001/jama.2023.8061 · DOI
- Sadry, 2013, Emerging combinatorial hormone therapies for the treatment of obesity and T2DM, Nat. Rev. Endocrinol., 9, 425, 10.1038/nrendo.2013.47 · DOI · Paper page
- Liu, L., Nahata, M., Shi, H., Sun, Y., and Xie, M. (2024, April 01). Efficacy and Safety of Tirzepatide in Overweight or Obese Adults without Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Preprint (Version 1). Available online: https://www.researchsquare.com/article/rs-4184273/v1. · DOI
- Ravussin, 2009, Enhanced weight loss with pramlintide/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy, Obesity, 17, 1736, 10.1038/oby.2009.184 · DOI · Paper page
- Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons. · DOI · Paper page
- Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: Checklist and explanations, Ann. Intern. Med., 162, 777, 10.7326/M14-2385 · DOI · Paper page
Cited by
Managing early-onset type 2 diabetes in the individual and at the population level
Misra, S., Khunti, K., Goyal, A., Gable, D., Armocida, B., Tandon, N., Sachdev, P., Wild, S. H., Hivert, M.-F., & Beran, D. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01067-0 · Cited by 47
Metadata
- Authors
- Liu, L., Shi, H., Shi, Y., Wang, A., Guo, N., Tao, H., & Nahata, M. C.
- Affiliations
- Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
- Department of Bariatric and Metabolic Surgery, Fudan University Affiliated Huadong Hospital, Shanghai 201203, China
- Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 200437, China
- Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100054, China
- Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200331, China
- Department of Gastroenterology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510180, China
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2024-06-24
- Volume
- 17
- Issue
- 7
- Pages
- 828
- ISSN
- 1424-8247
- Cited by
- 40
- References
- 22
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.